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Introduction
Persistent albuminuria is the hallmark of diabetic nephrop-
athy, a condition that is characterized by progressively ris-
ing arterial blood pressure, declining glomerular filtration 
(GFR) rate and a high risk of end-stage renal disease 
(ESRD) and fatal or non-fatal cardiovascular disease 
(CVD).1 Next to blood pressure, baseline urinary albumin 
excretion, initial reduction in albumin excretion with ther-
apy and residual albumin excretion, despite renoprotective 
treatment, are all closely associated with decline in GFR, 
risk of ESRD, CVD events and mortality in diabetes.2–5 In 
addition, reduced GFR (<60 ml/min per 1.73m2) is an inde-
pendent risk factor for both ESRD and CVD.6,7 Type 2 dia-
betes and chronic kidney disease (CKD) are both 
characterized by increased activity of the renin–angioten-
sin–aldosterone system (RAAS).1 A novel renal metabolic 
receptor, GPR91, which binds succinate, is a direct link 
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between glycaemic control and renin release.8 Patients with 
poor glycaemic control have the highest renin release. 
Previous studies have demonstrated that the RAAS plays 
an important role in the development and progression of 
diabetic macro- and microangiopathy.1 Consequently 
RAAS blockade and blood pressure (BP) lowering have 
been a cornerstone in the prevention and treatment of car-
dio-renal complications in diabetic patients.9–12 Despite the 
improved outlook for type 2 diabetic patients there is still a 
large unmet need for new strategies to further reduce car-
diovascular and renal complications.
In 2007 an orally active direct renin inhibitor, aliskiren, 
was approved for treatment of hypertension. Aliskiren 
inhibits the first and rate-limiting step in the RAAS cascade, 
the conversion of angiotensinogen to angiotensin I, thereby 
reducing synthesis of all subsequent components of the cas-
cade, except plasma renin concentration.13 Several small 
studies with aliskiren in diabetes have demonstrated an anti-
proteinuric effect of monotherapy, enhanced albuminuria 
reduction with dual RAAS blockade and that the optimal 
dose for reno-protection is 300 mg once daily.14–16 In a mul-
tinational, randomized, double-blind study (AVOID), in 599 
patients with hypertension, type 2 diabetes and nephropathy, 
who are receiving the recommended renoprotective treat-
ment, we showed that the anti-proteinuric effect of aliskiren 
was independent of its blood pressure-lowering action.17
The aim of the present trial is to determine the effective-
ness and safety of direct renin inhibition with aliskiren com-
pared with placebo in type 2 diabetic patients at high risk of 
fatal and non-fatal renal and CVD events. Aliskiren is added 
to optimal treatment with an angiotensin converting enzyme 
inhibitor (ACEi) or angiotensin receptor blocker (ARB), 
along with other evidence-based cardiovascular protective 
therapy, which is recommended in all patients.
Materials and methods
The detailed rationale, study design and methods for 
ALTITUDE have been published elsewhere.18
Study population
We are studying type 2 diabetic patients at high risk for 
fatal and non-fatal cardiovascular and renal events. The 
patients are required to fulfil the following inclusion crite-
ria: persistent albuminuria (urinary albumin/creatinine 
ratio, UACR ≥ 200 mg/g) in two out of three consecutive 
first morning void urine samples, or an eGFR ≥ 30 < 60 ml/
min per 1.73 m2 calculated by the abbreviated MDRD study 
equation19 and persistent microalbuminuria (UACR ≥ 20 
mg/g) in two out of three consecutive first morning void 
urine samples or a history of CVD. In ALTITUDE microal-
buminuria was defined as a UACR 20–200 mg/g, as com-
pared with the standard definition of 30–300 mg/g, because 
all patients were already on therapy with an ACEi or ARB.
The protocol has been approved by the Ethics Review 
Committee/Institutional Review Board affiliated with each 
centre. The study is being conducted in accordance with 
Good Clinical Practice, Declaration of Helsinki 2002. All 
participants provided written informed consent. An exter-
nal independent data monitoring committee (DMC) will 
monitor safety throughout this study. The trial has been reg-
istered on Clinicaltrials.gov, NCT00549757.
Medical management
It is recommended that all patients receive optimal doses of 
an ACEi or ARB, optimal antihypertensive therapy for 
renal and CVD protection and primary or secondary pre-
ventive therapy with a statin, anti-platelet therapy and a 
beta-blocker treatment, as indicated by local guidelines. 
Glycaemic control is also recommended to follow local 
guidelines.
Primary objective
The primary endpoint is the composite of cardiovascular 
(CV) death, resuscitated sudden death, non-fatal myocar-
dial infarction (MI), non-fatal stroke, unplanned hospitali-
zation for heart failure, ESRD or renal death or doubling of 
baseline serum creatinine concentration, sustained for at 
least a month, which will be analysed as time to the first 
event. The onset of ESRD is defined as initiation of persis-
tent dialysis, renal transplantation or a serum creatinine 
concentration >6.0 mg/dl (530 µmol/L). Renal death is 
defined as death attributable to kidney failure or due to lack 
of renal replacement therapy because dialysis or transplan-
tation is unavailable, not provided or refused.
Results
Enrolment
From 10 October 2007 through 23 June 2010, a total of 
21,152 patients from 36 countries were screened and 8606 
(41%) of these were randomized. The geographical distribu-
tion of the randomized patients is shown in Table 1. The 
main reasons for screen failures were: patients had unac-
ceptable laboratory values (47.3%), did not meet diagnostic/
severity criteria (40.1%) or 7.3% withdrew their consent.
Overall cohort
Table 2 shows the baseline characteristics of the rand-
omized population. At the time of randomization 56.6% 
were treated with insulin, and biguanides and sulphonylu-
reas were used by 46.2% and 31.9%, respectively (Table 3). 
An ACEi was used by 44.2% and the remaining 55.9% of 
the patients used an ARB; 63.2% used loop/thiazide diuret-
ics at baseline. The frequency of diuretic use at baseline 
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varied considerably from country to country (range: 26.1% 
to 89.8%, data not shown). The Asian countries had the 
lowest use of diuretics, while the European countries had 
the highest use. Statin treatment was used by 65.1% and 
aspirin or other anti-platelet agents were used by 62.5%.
Patients with and without history of CVD
Several of the below-mentioned differences were dictated 
by the inclusion criteria. Patients with CVD were older and 
more often White, obese, and male, compared with patients 
without a history of CVD (Table 2). In patients with CVD, 
the level of UACR and frequency of micro–macroalbumi-
nuria was lower than in patients without a CVD history, 
whereas serum creatinine was higher. Mean blood pressure 
and HbA1c were similar, while cholesterol and triglycerides 
were lower in patients with CVD compared with those 
without. Patients with CVD were more likely to report 
beta-blocker, diuretic, statin, aspirin or other anti-platelet 
agent use compared with those who did not have CVD 
(Table 3).
Patients with and without macroalbuminuria
Patients with macroalbuminuria were younger, more often 
non-White, less likely to have CVD and had a lower aver-
age creatinine concentration compared with those without 
macroalbuminuria (Table 2). Blood pressure, HbA1c and 
LDL-cholesterol tended to be higher in patients with overt 
albuminuria. Use of CVD-protective therapy was less com-
mon in patients with macroalbuminuria, while insulin use 
was more frequent, compared with those without macroal-
buminuria (Table 3).
Comparison with the ONTARGET study
Both ALTITUDE and ONTARGET20 evaluate the impact 
of dual RAAS blockade on CVD events, but drug classes 
differ (ACEi and ARB used in ONTARGET). The primary 
composite endpoint is identical, but is expanded with 
ESRD or renal death or doubling of baseline serum creati-
nine concentration (sustained for at least one month) in 
ALTITUDE.18 The ALTITUDE patients are characterized 
by higher frequency of arterial hypertension (94.4% vs. 
69%), micro–macroalbuminuria (83.9% vs. 17.1%), CKD 
stage 3 (65% vs. 24%) and use of diuretics (63.2% vs. 
28.0%) compared with the ONTARGET patients. All 
patients in ALTITUDE have type 2 diabetes, while this was 
present in 37.5% in the ONTARGET study. CVD history 
was more common in the ONTARGET patients (85.0% vs. 
47.9%).
Conclusions
A key aim of treating type 2 diabetes is to prevent or reduce 
development of micro- or macrovascular complications, 
and to try to achieve as near normal quality and quantity of 
life as possible. Multifactorial intervention – with improved 
glycaemic regulation and the use of RAAS blockers, aspi-
rin and lipid-lowering agents – has been shown to reduce 
the risk of fatal and non-fatal renal and cardiovascular 
events.21 However, the impact on preventing CVD events 
by different interventions (per 1000 patient-years of treat-
ment) varies considerably: 12 per 4 mmHg lower systolic 
blood pressure, 8 per 1 mmol/L lower LDL-cholesterol and 
3 per 0.9% lower HbA1c.22 A recent meta-analysis of rand-
omized controlled trials of glycaemic regulation concluded: 
‘when only high quality studies are considered, no benefit 
was associated with intensive treatment, and the risk of 
severe hypoglycaemia doubled’.23 In the ADVANCE study 
severe hypoglycaemia was strongly associated with 
increased risk fatal and non-fatal CVD events.24 However, 
no relationship was found between repeated episodes of 
severe hypoglycaemia, vascular outcomes or death in the 
ADVANCE study.
The primary objective of ALTITUDE is to evaluate the 
efficacy and safety of aliskiren 300 mg once daily added to 
full recommended conventional therapy (including a maxi-
mum dose of an ACEi or ARB) in patients with type 2 dia-
betes who are at high risk of cardiovascular and renal 
Table 1. ALTITUDE – study global status by geographic distribution
Region Screened Randomized Screen  
failed
Randomization 
rate
US/Canada 3520 1217 2303 35%
Latin America Argentina, Brazil, Colombia, Guatemala, Peru, Venezuela 3456 1075 2381 31%
Europe Austria, Belgium, Czech Republic, Denmark, Finland, France, 
Germany, Greece, Hungary, Italy, Lithuania, Norway, Portugal, 
Slovakia, Spain, Sweden, Switzerland, Netherlands, Turkey, UK
8151 3574 4577 44%
Asia Japan, Korea, Singapore, Taiwan, Thailand 1483 844 639 57%
China 2767 1228 1539 45%
India 1279 476 803 37%
S. Africa 496 192 304 39%
Total 21,152 8606 12478 41%
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Table 2. Baseline characteristics of the overall study cohort and by subgroup; randomized population
Variable Total (N = 8606) Cardiovascular  
disease historya
Urinary albumin to  
creatinine ratio ≥ 200 mg/gb
 Yes (N = 4118) No (N = 4488) Yes (N = 5023) No (N = 3583)
Age, years 65.0 (58, 72) 68.0 (62, 74) 62.0 (55, 69) 62.0 (55, 69) 69.0 (63, 75)
Male, n (%) 5851 (68.0) 2991 (72.6) 2860 (63.7) 3437 (68.4) 2414 (67.4)
Race, n (%)  
 White 4873 (56.6) 2902 (70.5) 1971 (43.9) 2332 (46.4) 2541 (70.9)
 African American 280 (3.3) 126 (3.1) 154 (3.4) 164 (3.3) 116 (3.2)
 Asian 2726 (31.7) 809 (19.6) 1917 (42.7) 2048 (40.8) 678 (18.9)
 Native American 10 (0.1) 9 (0.2) 1 (0.0) 7 (0.1) 3 (0.1)
 Other 703 (8.2) 265 (6.4) 438 (9.8) 463 (9.2) 240 (6.7)
 Pacific island 14 (0.2) 7 (0.2) 7 (0.2) 9 (0.2) 5 (0.1)
Body mass index (kg/m2) 29.1 (25.7, 33.2) 30.0 (26.5, 34.0) 28.2 (25.1, 32.3) 28.5 (25.2, 32.8) 29.8 (26.4, 33.6)
Known duration of diabetes, n (%)  
 ≤ 1 year 288 (3.3) 140 (3.4) 148 (3.3) 139 (2.8) 149 (4.2)
 > 1–5 years 1229 (14.3) 556 (13.5) 673 (15.0) 669 (13.3) 561 (15.7)
 ≥ 5 years 7086 (82.3) 3422 (83.1) 3664 (81.6) 4214 (83.9) 2871 (80.1)
Retinopathy, % 36.8 31.3 41.8 43.2 27.7
Laser treatment, n (%) 1457 (16.9) 618 (15.0) 839 (18.7) 1009 (20.1) 448 (12.5)
Peripheral  
Neuropathy - n (%)
2397 (27.9) 1072 (26.0) 1325 (29.5) 1583 (31.5) 814 (22.7)
Any of the following  
cardiovascular diseases, n (%)
4118 (47.9) 4118 (100.0) 0 (0.0) 1715 (34.1) 2403 (67.1)
Congestive heart failure  
or hospitalization for  
congestive heart failure
960 (11.2) 960 (23.3) 0 (0.0) 355 (7.1) 605 (16.9)
Unstable angina pectoris 830 (9.6) 830 (20.2) 0 (0.0) 278 (5.5) 552 (15.4)
Myocardial infarction 1434 (16.7) 1434 (34.8) 0 (0.0) 484 (9.6) 950 (26.5)
Prior percutaneous coronary 
intervention
1224 (14.2) 1224 (29.7) 0 (0.0) 437 (8.7) 787 (22.0)
Prior coronary artery bypass graft 1067 (12.4) 1067 (25.9) 0 (0.0) 326 (6.5) 741 (20.7)
Stroke 852 (9.9) 852 (20.7) 0 (0.0) 378 (7.5) 474 (13.2)
Transient ischaemic attack 353 (4.1) 353 (8.6) 0 (0.0) 153 (3.0) 200 (5.6)
Amputation of toe/foot/leg 341 (4.0) 341 (8.3) 0 (0.0) 226 (4.5) 115 (3.2)
Atrial fibrillation 736 (8.6) 736 (17.9) 0 (0.0) 270 (5.4) 466 (13.0)
Pacemaker implanted 209 (2.4) 209 (5.1) 0 (0.0) 72 (1.4) 137 (3.8)
Smoking history, %  
 Current 13.1 9.6 16.4 17.4 7.2
 Ex-smoker 36.4 44.8 28.7 32.9 41.3
Diastolic blood pressure, mmHg 74.3  
(67.3, 80.7)
73.0 
(66.3, 79.7)
75.0 
(68.3, 81.3)
75.3  
(69.0, 81.7)
72.0  
(65.7, 79.0)
Systolic blood pressure, mmHg 134.7  
(126.0, 149.7)
136.3 
(126.7, 150.3)
133.7 
(125.7, 148.7)
135.7 
(126.7, 151.3)
133.7
(125.0, 147.3)
Pulse pressure, mmHg 62.0 
(52.0, 73.3)
63.7
(53.3, 75.3)
60.3 
(50.7, 71.3)
61.3
(51.3, 73.3)
62.3 
(52.7, 73.3)
Serum creatinine, µmol/L 115.0 
(91.0, 137.0)
119.0
(99.0, 139.0)
109.6
(83.0, 134.0)
105.0
(80.0, 134.0)
121.0
(106.0, 139.0)
eGFR, ml/min per 1.73 m2 51.7 
(41.9, 64.9)
49.2
(41.4, 59.3)
54.1
(42.3, 73.4)
57.4
(43.3, 78.1)
48.0 
(40.8, 54.6)
eGFR, ml/min per 1.73 m2 category, n (%)  
 < 30 220 (2.6) 108 (2.6) 112 (2.5) 153 (3.0) 67 (1.9)
 ≥ 30 to < 45 2574 (29.9) 1352 (32.8) 1222 (27.2) 1249 (24.9) 1325 (37.0)
 ≥ 45 to < 60 3024 (35.1) 1667 (40.5) 1357 (30.2) 1287 (25.6) 1737 (48.5)
 ≥ 60 2781 (32.3) 985 (23.9) 1796 (40.0) 2331 (46.4) 450 (12.6)
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Table 3. Baseline medication of the overall study cohort and by subgroup; randomized population
Medication, n (%) Total (N =8606) Cardiovascular  
disease historya
Urinary albumin to  
creatinine ratio ≥ 200 mg/gb
 Yes (N =4118) No (N =4488) Yes (N =5023) No (N =3583)
Insulin of any kind 4871 (56.6) 2254 (54.7) 2617 (58.3) 3124 (62.2) 1747 (48.8)
Biguanides 3982 (46.3) 1859 (45.1) 2123 (47.3) 2367 (47.1) 1615 (45.1)
Sulphonylureas 2742 (31.9) 1309 (31.8) 1433 (31.9) 1526 (30.4) 1216 (33.9)
Thiazolidinediones 725 (8.4) 282 (6.8) 443 (9.9) 411 (8.2) 314 (8.8)
Angiotensin-converting-enzyme inhibitor 3807 (44.2) 2089 (50.7) 1718 (38.3) 2038 (40.6) 1769 (49.4)
Angiotensin-II-receptor blocker 4814 (55.9) 2041 (49.6) 2773 (61.8) 2997 (59.7) 1817 (50.7)
Beta-blocker 4312 (50.1) 2716 (66.0) 1596 (35.6) 2184 (43.5) 2128 (59.4)
Calcium channel blocker 5265 (61.2) 2366 (57.5) 2899 (64.6) 3341 (66.5) 1924 (53.7)
Loop/thiazide diuretics 5438 (63.2) 2907 (70.6) 2531 (56.4) 2910 (57.9) 2528 (70.6)
Aldosterone receptor blocker 30 (0.3) 23 (0.6) 7 (0.2) 6 (0.1) 24 (0.7)
Statin 5600 (65.1) 3169 (77.0) 2431 (54.2) 2971 (59.1) 2629 (73.4)
Other lipid lowering agent 1392 (16.2) 799 (19.4) 593 (13.2) 713 (14.2) 679 (19.0)
Aspirin only 4183 (48.6) 2270 (55.1) 1913 (42.6) 2258 (45.0) 1925 (53.7)
Aspirin or other anti-platelet agent 5381 (62.5) 3209 (77.9) 2172 (48.4) 2803 (55.8) 2578 (72.0)
Denominator is the total number of patients in each column. Baseline medications are defined as the medications taken at baseline visit (randomiza-
tion visit). Indapamide (classified as other diuretics) is not included in loop/thiazide diuretics.
aThe subgrouping of cardiovascular disease history is based on the cardiovascular diseases listed in Table 2.
bIf baseline urinary albumin to creatinine ratio (UACR) is missing, then subgrouping of UACR ≥ 200 mg/g (Yes/No) is taken from randomization 
stratification.
Variable Total (N = 8606) Cardiovascular  
disease historya
Urinary albumin to  
creatinine ratio ≥ 200 mg/gb
 Yes (N = 4118) No (N = 4488) Yes (N = 5023) No (N = 3583)
Urinary albumin to creatinine  
ratio, mg/gc
198.9 
(56.2, 886.0)
88.3 
(13.1, 513.7)
410.4
(184.5, 1205.7)
772.5
(353.7, 1502.6)
27.7
(8.8, 90.3)
Urinary albumin to creatinine  
ratio, mg/g, category, n (%)d
 
< 20 1240 (14.4) 1162 (28.2) 78 (1.7) 0 (0.0) 1240 (34.6)
≥ 20 to < 200 2210 (25.7) 1120 (27.2) 1090 (24.3) 0 (0.0) 2210 (61.7)
≥ 200 5012 (58.2) 1707 (41.5) 3305 (73.6) 5012 (99.8) 0 (0.0)
Albumin (g/L) 43.0
(41.0, 45.0)
43.0
(41.0, 45.0)
43.0
(40.0, 45.0)
42.0
(39.0,44.0)
44.0
(42.0, 46.0)
Haemoglobin A1C, % 7.5 (6.6, 8.6) 7.4 (6.6, 8.4) 7.6 (6.7, 8.7) 7.6 (6.8, 8.9) 7.3(6.5, 8.2)
Haemoglobin (g/L) 130.0
(119, 143)
132.0
(121.0, 144.0)
130.0
(118.0, 142.0)
130.0
(119, 143)
131.0
(121, 143)
Total cholesterol, mmol/L 4.4 (3.7, 5.1) 4.1 (3.5, 4.8) 4.6 (3.9, 5.3) 4.6 (3.9, 5.4) 4.1 (3.5, 4.8)
LDL cholesterol, mmol/L 2.4 (1.9, 3.0) 2.2 (1.7, 2.8) 2.6 (2.0, 3.2) 2.5 (2.0, 3.2) 2.2 (1.7, 2.7)
HDL cholesterol, mmol/L 1.1 (1.0, 1.4) 1.1 (0.9, 1.3) 1.2 (1.0, 1.4) 1.1 (1.0, 1.4) 1.1 (0.9, 1.3)
Triglycerides, mmol/L 1.80
(1.30, 2.53)
1.70 
(1.20, 2.50)
1.80
(1.30, 2.60)
1.80
(1.30, 2.70)
1.70 
(1.20, 2.40)
Serum potassium, mmol/L 4.5 (4.2, 4.8) 4.5 (4.2, 4.8) 4.5 (4.2, 4.8) 4.5 (4.2, 4.8) 4.5 (4.2, 4.8)
Median with first and third quartiles indicated except for urinary albumin to creatinine ratio (UACR). Denominator is the total number of patients in 
each column.
aThe subgrouping of cardiovascular disease history is based on the cardiovascular diseases listed in this table.
bIf baseline UACR is missing, then subgrouping of UACR ≥200 mg/g (Yes/No) is taken from randomization stratification.
cUACR is calculated by using the geometric mean of last three measurements prior to randomization visit date. Geometric mean with first and third 
quartiles indicated.
dUACR category definition is based on the median of last three measurements prior to randomization visit date.
Table 2. (Continued)
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events. At baseline, the majority of patients had micro- or 
macroalbuminuria and stage 3 CKD, i.e. are at high risk for 
both renal events and CVD. In addition, nearly half already 
had a history of CVD. Indeed, this may be an underestimate 
as a recent study suggested that more than 50% of asymp-
tomatic patients with type 2 diabetes and an UACR above 
30 mg/g had significant coronary arterial disease.25
At randomization 220 patients had stage 4 CKD, except 
12 patients with pre-randomized determination of eGFR 
below 30 ml/min per 1.73m2, the remaining 208 had pre-
randomized determination above 30 ml/min per 1.73m2. It 
should be mentioned that the enrolment criteria led to a 
lower eGFR in CVD patients as compared with patients 
with macroalbuminuria, since reduced eGFR was not a 
requirement in the latter group.
A recent systemic review of event rates in clinical trials 
in diabetes mellitus concluded:26 ‘Trials including diabetic 
subjects without cardiovascular disease or proteinuria gen-
erate few events, and require substantial participant num-
bers to achieve adequate power. However, presence of 
coexisting cardiovascular disease or proteinuria increases 
event rate multiple-fold’. The enrolment criteria in 
ALTITUDE reflect that knowledge.
At randomization the patients were already fairly well 
treated, regarding important cardiovascular and renal risk 
factors, such as blood pressure, lipid levels, glycaemic regu-
lation, haemoglobin and low frequency of smoking. 
Approximately 80% of the patients were treated with a lipid 
lowering agent and 63% with anti-platelet therapy, with even 
higher rates of use of these drugs in patients with CVD. 
Insulin, as expected, was the most commonly prescribed 
hypoglycaemic drug, followed by metformin. The common 
use of metformin is notable in relation to the reduced renal 
function in the patients, but reflects the much wider indica-
tion for biguanides nowadays. The main concern for lactic 
acidosis is in patients with an eGFR <30 ml/min per 1.73 m2.
CKD and the diabetic state are characterized by enhanced 
tissue RAAS activity27 and sodium and fluid retention. 
Consequently, diuretic treatment should be considered in 
nearly all of our patients. The benefits from diuretics are 
numerous: reduced sodium and fluid retention, improved 
effect of RAAS blockade, improved blood pressure control 
and reduced frequency of hyperkalaemia. However, only 
63% of the patients in ALTITUDE are prescribed diuretics 
at baseline.
Aliskiren differs from an ACEi and ARB in blocking the 
first and rate-limiting step in the RAAS, leading to suppres-
sion of all RAAS hormones including plasma renin activity, 
but not plasma renin concentration. In addition, the drug 
has a half-life of approximately 40 hours, with a trough-to-
peak ratio of 0.9 for the 300 mg dose. Enhanced and more 
complete blockade of the intrarenal RAAS has also been 
demonstrated.28 Animal studies suggest that aliskiren 
reduces the number of (pro)renin receptors in the kidney.29 
Since non-dipping of night-time blood pressure and 
enhanced diurnal blood pressure variability are frequently 
present in patients with CKD and long standing diabe-
tes,30–32 long lasting stable blood pressure reduction as 
obtained with aliskiren might prove beneficial.
What is key, however, to the hypothesis tested in 
ALTITUDE is that aliskiren has additional potentially ben-
eficial actions when added to an ACEi or ARB and that 
these might translate into improved clinical outcomes. In 
AVOID, when combined with an ARB, aliskiren lowered 
urinary albumin excretion in patients with diabetic nephrop-
athy.17 Numerous studies2–4 have documented that the initial 
treatment-induced reduction in albuminuria is highly pre-
dictive of reduction of fatal and non-fatal renal and cardio-
vascular events including the most recent analysis of the 
ONTARGET and TRANSCEND studies. When added to an 
ACEi or an ARB in patients with chronic heart failure, 
aliskiren reduced brain natriuretic peptide (BNP), a change 
also predictive of improved outcome in this condition31. 
Although adding aliskiren to an ACEi or ARB did not lead 
to greater regression of left ventricular mass in hypertensive 
patients with left ventricular hypertrophy33 or reduce left 
ventricular remodelling after MI34 overall in ALLAY and 
ASPIRE, there was a trend to more regression and less 
remodelling with aliskiren in the subgroup of patients with 
diabetes, possibly because these patients have enhanced 
RAAS activity. More regression of left ventricular hypertro-
phy in hypertension and left ventricular remodelling after 
MI are both predictive of better clinical outcomes.
In conclusion, the ALTITUDE study will determine the 
potential cardio-renal benefit and safety of the direct renin 
inhibitor aliskiren in combination with ACEi or ARB in a 
broad range of high risk patients with type 2 diabetes.
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